The role of mitogen- and stress-activated protein kinase 1 and 2 in chronic skin inflammation in mice

2010 ◽  
Vol 20 (2) ◽  
pp. 140-145 ◽  
Author(s):  
Trine Bertelsen ◽  
Lars Iversen ◽  
Jette Lindorff Riis ◽  
J. Simon C. Arthur ◽  
Bo Martin Bibby ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. e93665 ◽  
Author(s):  
Silvana Zgraggen ◽  
Reto Huggenberger ◽  
Katrin Kerl ◽  
Michael Detmar


2011 ◽  
Vol 91 (3) ◽  
pp. 271-278 ◽  
Author(s):  
L Iversen ◽  
LL Lilleholt ◽  
C Johansen ◽  
JS Arthur ◽  
A Funding ◽  
...  


Antioxidants ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1179
Author(s):  
Andrzej Kazimierz Jaworek ◽  
Jacek Cezary Szepietowski ◽  
Przemysław Hałubiec ◽  
Anna Wojas-Pelc ◽  
Jolanta Jaworek

Atopic dermatitis (AD) is common inflammatory dermatosis, typically with chronic and recurrent course, which significantly reduces the quality of life. Sleep disturbances are considered to be remarkably burdensome ailments in patients with AD, and are routinely included during assessment of disease severity. Therefore, endogenous substances engaged in the control of circadian rhythms might be important in pathogenesis of AD and, possibly, be used as biomarkers of disease severity or even in development of novel therapies. Melatonin (MT), the indoleamine produced by pineal gland (but also by multiple other tissues, including skin), plays a pivotal role in maintaining the sleep/wake homeostasis. Additionally, it possesses strong antioxidant and anti-inflammatory properties, which might directly link chronic skin inflammation and sleep abnormalities characteristic of AD. The objective of this work is to systematically present and summarize the results of studies (both experimental and clinical) that investigated the role of MT in the AD, with a focus on the antioxidant and immunomodulatory effects of MT.



2010 ◽  
Vol 207 (10) ◽  
pp. 2255-2269 ◽  
Author(s):  
Reto Huggenberger ◽  
Stefan Ullmann ◽  
Steven T. Proulx ◽  
Bronislaw Pytowski ◽  
Kari Alitalo ◽  
...  

The role of lymphangiogenesis in inflammation has remained unclear. To investigate the role of lymphatic versus blood vasculature in chronic skin inflammation, we inhibited vascular endothelial growth factor (VEGF) receptor (VEGFR) signaling by function-blocking antibodies in the established keratin 14 (K14)–VEGF-A transgenic (Tg) mouse model of chronic cutaneous inflammation. Although treatment with an anti–VEGFR-2 antibody inhibited skin inflammation, epidermal hyperplasia, inflammatory infiltration, and angiogenesis, systemic inhibition of VEGFR-3, surprisingly, increased inflammatory edema formation and inflammatory cell accumulation despite inhibition of lymphangiogenesis. Importantly, chronic Tg delivery of the lymphangiogenic factor VEGF-C to the skin of K14-VEGF-A mice completely inhibited development of chronic skin inflammation, epidermal hyperplasia and abnormal differentiation, and accumulation of CD8 T cells. Similar results were found after Tg delivery of mouse VEGF-D that only activates VEGFR-3 but not VEGFR-2. Moreover, intracutaneous injection of recombinant VEGF-C156S, which only activates VEGFR-3, significantly reduced inflammation. Although lymphatic drainage was inhibited in chronic skin inflammation, it was enhanced by Tg VEGF-C delivery. Together, these results reveal an unanticipated active role of lymphatic vessels in controlling chronic inflammation. Stimulation of functional lymphangiogenesis via VEGFR-3, in addition to antiangiogenic therapy, might therefore serve as a novel strategy to treat chronic inflammatory disorders of the skin and possibly also other organs.



Author(s):  
Andrzej Kazimierz Jaworek ◽  
Jacek C Szepietowski ◽  
Przemysław Hałubiec ◽  
Anna Wojas-Pelc ◽  
Jolanta Jaworek

Atopic dermatitis (AD) is common inflammatory dermatosis, typically with chronic and recurrent course, which significantly reduces the quality of life. Sleep disturbances are considered to be remarkably burdensome ailments in the patients with AD, and are routinely included during assessment of disease severity. Therefore, endogenous substances engaged in the control of circadian rhythms might be important in pathogenesis of AD and, possibly, be used as biomarkers of disease severity or even in development of novel therapies. Melatonin (MT), the indoleamine produced by pineal gland (but also by multiple other tissues, including skin), plays a pivotal role in maintaining the sleep/wake homeostasis. Additionally, it possess strong antioxidant and anti-inflammatory properties, which might directly link chronic skin inflammation and sleep abnormalities characteristic of AD. The objective of this work is to systematically present and summarize the results of studies (both experimental and clinical) that investigated the role of MT in the AD, with focus on the antioxidant and immunomodulatory effects of MT.



2010 ◽  
Vol 48 (08) ◽  
Author(s):  
N Azoitei ◽  
GV Pusapati ◽  
A Kleger ◽  
C Brunner ◽  
F Genze ◽  
...  


2013 ◽  
Vol 51 (08) ◽  
Author(s):  
A Becher ◽  
A Staab ◽  
F Genze ◽  
S Bobrovich ◽  
N Azoitei ◽  
...  
Keyword(s):  


1986 ◽  
Vol 113 (1_Suppl) ◽  
pp. S63-S64
Author(s):  
A. K. MUKHOPADHYAY ◽  
H. G. BOHNET


Sign in / Sign up

Export Citation Format

Share Document